<<

OFFICE OF THE DIRECTOR Kate Brown, Governor

500 Summer St NE E20 Salem OR 97301 Voice: 503-947-2340 Fax: 503-947-2341

COVID-19 treatments known as monoclonal have the potential to save lives and relieve the burden on our nation’s health care system. Monoclonal are now available in subcutaneous in addition to intravenous formulation.

How do monoclonal antibodies work? Monoclonal antibodies treatments mimic our ’s response to SARS-CoV-2 (the that causes COVID-19) and are available to eligible, non-hospitalized patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.

Who is eligible to receive treatment? People ages 12 and older and who weigh >40kg who:

• Have tested positive for COVID-19 • are experiencing mild or moderate symptoms of COVID-19 • had first symptoms within the last 10 days • are considered high risk for going into the hospital because of age >65, weight, , immunosuppressive disease or treatment or some other chronic illnesses. See the full list.

Who is eligible to receive post exposure prophylaxis with monoclonal antibodies? People ages 12 and older and who are exposed or at high risk for exposure (such as in congregate settings) and are:

• Incompletely vaccinated - i.e. unvaccinated or partially vaccinated • Fully vaccinated but expected to not have as strong an because of immunocompromising illness or being on immunosuppressive .

Who give should this treatment? Oregon Health Authority (OHA) encourages all providers to offer monoclonal antibody treatment to appropriate high-risk patients with COVID-19 infection or exposure to reduce the risk of hospitalization and symptomatic disease. The subcutaneous formulation can be administered by any qualified provider in the state of Oregon. Patients must be observed for 1

1 of 2 OHA 8313 (8/26/2021) hour following administration because of the rare risk of . Details on logistics and administration of this new product are available in the updated HHS playbook: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Documents/USG- COVID19-Tx-Playbook.pdf

Is monoclonal antibody treatment available in Oregon? One product (Casirivimab/Imdevimab) is currently available in Oregon through Health and Human Services (HHS) at no charge. It is effective against the Delta variant, which is currently the predominant variant circulating in Oregon. This product is available to ship now, in both intravenous and subcutaneous formulations. Two other products are available for commercial purchase directly through manufacturer and these are effective against the Delta variant. Click here to find treatment locations near you https://protect- public.hhs.gov/pages/therapeutics-distribution.

Is monoclonal antibody treatment effective in fighting COVID-19? When used for treatment of mild to moderate COVID-19, Casirivimab/Imdevimab reduces the risk of hospitalization by 50% in clinical trials leading to authorization. Casirivimab/Imdevimab has been shown to reduce the risk of symptomatic COVID-19 by 81% when used as post- exposure prophylaxis. Additional information regarding this data is available via the EUA Fact sheet for health care providers. (https://www.fda.gov/media/145611/download).

Where can I get more information on using monoclonal antibody treatments? While monoclonal antibody treatments are available for direct ordering through HHS, please feel free to contact OHA with any questions you may have: [email protected] Here is a link to the CDC’s COVID-19 Monoclonal Antibody Therapeutics Communications Toolkit for health care providers, health system administrators, treatment sites and others.

Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or [email protected]

2 of 2 OHA 8313 (8/26/2021)